Native Antigen releases coronavirus antigens

By staff writers

February 13, 2020 -- The Native Antigen Co. has introduced a line of coronavirus antigens from the emerging Wuhan strain, a move it said will support research and the development of diagnostics and vaccines.

The antigens were derived from the novel coronavirus (2019-nCoV) using the company's proprietary VirtuE expression system. The system introduces proper protein folding and post-translational modifications to recombinant proteins, which are essential for full biological and antigenic activity, according to the company.

WHO officially names coronavirus disease COVID-19
The World Health Organization (WHO) on February 11 announced an official designation for the disease caused by the novel coronavirus (2019-nCoV), naming...
CDC wrestles with coronavirus test problems in states
The U.S. Centers for Disease Control and Prevention (CDC) reported that there have been problems with some of the 2019-nCoV test kits sent out to labs...
CMS offers guidance on use of CDC coronavirus test
The U.S. Centers for Medicare and Medicaid Services (CMS) on February 6 offered guidance to medical labs in the field on how to use a diagnostic test...
Wuhan coronavirus RT-PCR tests deliver results fast
Scientists in Hong Kong and China have developed rapid reverse transcription polymerase chain reaction (RT-PCR) tests that may be used to identify and...
FDA shares CDC test with labs on emergency use basis
In a breakthrough for diagnostics amid the Wuhan coronavirus crisis, the U.S. Food and Drug Administration (FDA) has issued an emergency use authorization...

Copyright © 2020

Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.